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Atomoxetine restores the response inhibition
network in Parkinson’s disease
Charlotte L. Rae,1,2 Cristina Nombela,1 Patricia Va´zquez Rodrı´guez,1 Zheng Ye,1
Laura E. Hughes,1,2 P. Simon Jones,1 Timothy Ham,1 Timothy Rittman,1
Ian Coyle-Gilchrist,1 Ralf Regenthal,3 Barbara J. Sahakian,4,5 Roger A. Barker,1 Trevor
W. Robbins4,6 and James B. Rowe1,2,4
Parkinson’s disease impairs the inhibition of responses, and whilst impulsivity is mild for some patients, severe impulse control
disorders affect 10% of cases. Based on preclinical models we proposed that noradrenergic denervation contributes to the
impairment of response inhibition, via changes in the prefrontal cortex and its subcortical connections. Previous work in
Parkinson’s disease found that the selective noradrenaline reuptake inhibitor atomoxetine could improve response inhibition,
gambling decisions and reﬂection impulsivity. Here we tested the hypotheses that atomoxetine can restore functional brain net-
works for response inhibition in Parkinson’s disease, and that both structural and functional connectivity determine the behav-
ioural effect. In a randomized, double-blind placebo-controlled crossover study, 19 patients with mild-to-moderate idiopathic
Parkinson’s disease underwent functional magnetic resonance imaging during a stop-signal task, while on their usual dopaminergic
therapy. Patients received 40mg atomoxetine or placebo, orally. This regimen anticipates that noradrenergic therapies for behav-
ioural symptoms would be adjunctive to, not a replacement for, dopaminergic therapy. Twenty matched control participants
provided normative data. Arterial spin labelling identiﬁed no signiﬁcant changes in regional perfusion. We assessed functional
interactions between key frontal and subcortical brain areas for response inhibition, by comparing 20 dynamic causal models of
the response inhibition network, inverted to the functional magnetic resonance imaging data and compared using random effects
model selection. We found that the normal interaction between pre-supplementary motor cortex and the inferior frontal gyrus was
absent in Parkinson’s disease patients on placebo (despite dopaminergic therapy), but this connection was restored by atomoxetine.
The behavioural change in response inhibition (improvement indicated by reduced stop-signal reaction time) following atomoxetine
correlated with structural connectivity as measured by the fractional anisotropy in the white matter underlying the inferior frontal
gyrus. Using multiple regression models, we examined the factors that inﬂuenced the individual differences in the response to
atomoxetine: the reduction in stop-signal reaction time correlated with structural connectivity and baseline performance, while
disease severity and drug plasma level predicted the change in fronto-striatal effective connectivity following atomoxetine. These
results suggest that (i) atomoxetine increases sensitivity of the inferior frontal gyrus to afferent inputs from the pre-supplementary
motor cortex; (ii) atomoxetine can enhance downstream modulation of frontal-subcortical connections for response inhibition; and
(iii) the behavioural consequences of treatment are dependent on fronto-striatal structural connections. The individual differences
in behavioural responses to atomoxetine highlight the need for patient stratiﬁcation in future clinical trials of noradrenergic
therapies for Parkinson’s disease.
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Introduction
Parkinson’s disease is a complex disorder, in which the
cardinal features of bradykinesia, rigidity and tremor are
often accompanied by cognitive changes, even at diagnosis
(Nombela et al., 2014b; Yarnall et al., 2014). A dysexecu-
tive syndrome is common, including impairment of re-
sponse inhibition even in the absence of clinically severe
impulse control disorders (Napier et al., 2014). For ex-
ample, despite bradykinesia, Parkinson’s disease impairs
performance on a stop-signal task (Obeso et al., 2011a;
Nombela et al., 2014a; Ye et al., 2014). When stopping
an action, patients show abnormal responses in cortical
and subcortical regions, including the inferior frontal
gyrus, pre-supplementary motor area (preSMA), and sub-
thalamic nuclei (Frank et al., 2007; Ballanger et al., 2009).
To restore inhibitory control in Parkinson’s disease, we
drew on animal models that indicate a role for noradren-
aline in regulating response inhibition and impulsivity
(Eagle and Baunez, 2010; Bari et al., 2011; Bari and
Robbins, 2013), notwithstanding the contributory role of
fronto-striatal anatomical connections that are also abnor-
mal in Parkinson’s disease (Rae et al., 2012). Speciﬁcally,
we proposed that the loss of noradrenergic neurons and
their projections to the cortex (Goldstein et al., 2011) pro-
mote impulsivity, over and above changes in dopaminergic
function and dopaminergic treatment (Vazey and Aston-
Jones, 2012). The potential for the selective noradrenaline
reuptake inhibitor (SNRI) atomoxetine to modulate re-
sponse inhibition systems is suggested by recent studies in
Parkinson’s disease (Kehagia et al., 2014; Ye et al., 2015,
2016; Borchert et al., 2016), attention deﬁcit hyperactivity
disorder (Chamberlain et al., 2007; Cubillo et al., 2014),
and healthy subjects (Chamberlain et al., 2009).
Pharmacological enhancement of regional brain activity
is unlikely to alter behaviour if that region is functionally
disconnected from downstream effector mechanisms. As
neurotransmitters inﬂuence the communication between
neuronal populations, drug effects may be understood
better in terms of connectivity between regions rather
than activity within regions (Rowe, 2010; Moran et al.,
2013). For inhibitory control, communication between the
inferior frontal gyrus, preSMA and their projections to the
subthalamic nucleus are of particular relevance: lesion stu-
dies, transient interference by magnetic or electrical stimu-
lation, and neuroimaging provide convergent evidence that
interactions amongst these three regions are crucial for suc-
cessful response inhibition (Chambers et al., 2006; Frank
et al., 2007; Duann et al., 2009; Forstmann et al., 2012;
Aron et al., 2014; Rae et al., 2015).
We therefore used functional MRI to test the hypothesis
that atomoxetine restores connectivity within the inhibitory
control network in Parkinson’s disease. We used the ana-
lytic framework of Dynamic Causal Modelling (DCM,
Stephan et al., 2008), with evidence-based model selection
procedures that are robust in the context of Parkinson’s
disease (Rowe et al., 2010; Herz et al., 2014). Moreover,
the estimated parameters of directional connectivity from
one region to another correlate with neurophysiological
and anatomical markers of connectivity (Boudrias et al.,
2012; Rae et al., 2015). We sought additional evidence
from the correlations between the behavioural effect of
atomoxetine, functional connectivity, structural connectiv-
ity, drug levels and disease severity. Given the heterogeneity
of Parkinson’s disease, we predicted that disease severity
and white matter structure would inﬂuence changes in
functional connectivity in the inhibitory network and re-
sponse inhibition performance.
Materials and methods
Subjects and experimental design
Nineteen patients with idiopathic Parkinson’s disease (UK
Parkinson’s Disease Society Brain Bank Clinical Diagnostic
Criteria) were recruited from the PD Research Clinic at the
John van Geest Centre for Brain Repair. Inclusion criteria
were: (i) Hoehn and Yahr stage 1.5–3; (ii) age 50–80 years;
(iii) right-handed; and (iv) non-demented, using DSM-IV cri-
teria and Mini-Mental State Examination 526/30 at recent
clinical assessment. Exclusion criteria were (i) clinically signiﬁ-
cant current depression; (ii) contraindications to MRI or ato-
moxetine; and (iii) a history of signiﬁcant psychiatric disorder.
Patients were tested on their normal anti-parkinsonian dopa-
minergic medication (‘ON’ state). Levodopa equivalent daily
dose (LEDD) was calculated according to the formula of
Tomlinson et al. (2010).
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In a double-blind randomized placebo-controlled crossover
design, patients participated in two separate study sessions, at
least 6 days apart. The design is similar to that reported by Ye
et al. (2015) in a separate group of patients. Patients received
either 40mg of oral atomoxetine or placebo. Blood samples
were collected 2 h after drug administration, immediately
before transfer to the MRI scanner, coinciding with estimated
peak plasma concentration (Sauer et al., 2005). Mean concen-
tration was 327 ng/ml after atomoxetine (range 147–516ng/
ml) and 0 ng/ml after placebo.
Twenty healthy age- and sex-matched controls with no his-
tory of signiﬁcant neurological or psychiatric disorder partici-
pated in one session with no drug treatment, to provide
normative data on performance and imaging. The study was
approved by the local research ethics committee, and exempted
from Clinical Trials status by the UK Medicines and
Healthcare products Regulatory Authority. Participants gave
written informed consent. For participants’ demographic and
clinical features, see Table 1 (full medication details in
Supplementary Table 1).
Stop-signal task
Subjects performed a response inhibition task during func-
tional MRI, described in detail previously (Ye et al., 2014,
2015). In brief, there were 360 ‘Go’ trials (75%), 80 ‘stop’
trials (17%), and 40 ‘NoGo’ trials (8%), in a randomized
order. On Go trials, subjects responded to a left or right
black arrow (1000ms) with their right hand, followed by an
intertrial interval with a ﬁxation cross on blank background.
On stop trials, the initial Go cue was replaced after a variable
‘stop-signal delay’ by a red arrow (51500ms) and auditory
tone. The stimulus onset asynchrony was 2500ms. The stop-
signal delay was varied by an online algorithm (increment
50ms) to maintain successful inhibition on 50% of trials.
On NoGo trials, a red arrow and auditory tone appeared at
trial onset (equivalent to a stop-signal delay of 0ms). Given
the preclinical evidence of noradrenergic regulation of action
cancellation, and frequent use of stop-signal paradigms in
other disorders and comparative studies, we focus our analysis
on the stop trials. The stop-signal reaction time (SSRT) was
calculated by the integration method (Logan and Cowan,
1984), adjusting for Go trial omissions (Ye et al., 2015). We
expected individual differences in performance deﬁcits (Obeso
et al., 2011a; Ye et al., 2015), correlating ‘baseline’ SSRT on
placebo and the extent of improvement on atomoxetine
(Pearson’s correlation, SPSS).
MRI acquisition
Functional MRI data were acquired using T2*-weighted echo-
planar imaging (Siemens Trio 3T, 2000ms repetition time,
30ms echo time, 192  192 mm2 ﬁeld of view, 32 sequential
descending axial slices, 3 mm slice thickness, 0.75mm gap,
3  3 mm2 in-plane resolution). Eleven initial images were dis-
carded to allow steady-state magnetization. Five hundred and
twenty-ﬁve milliseconds after the start of the 12th image, the
task began with a ﬁxation cross of 500-ms duration, before the
ﬁrst arrow stimulus onset. A magnetization-prepared rapid ac-
quisition gradient echo (MPRAGE) T1-weighted structural
image was acquired for co-registration and normalization
(2300ms repetition time, 2.86ms echo time,
1.25  1.25  1.25mm resolution).
To exclude signiﬁcant drug-induced changes in cerebral per-
fusion, we used pulsed arterial spin labelling (PASL) after the
stop-signal task (PICORE-Q2T-PASL, 2500ms repetition time,
13ms echo time, 256  256 mm2 ﬁeld of view, nine slices,
8mm slice thickness, 2mm gap, ﬂip angle 90, 700ms inver-
sion time 1, 1800ms, inversion time 2 ﬁrst slice, 1600ms sat-
uration stop time, 100mm tag width and 180mm gap, 90
repetitions giving 45 tag–control pairs). A single-shot EPI
(M0) equilibrium magnetization scan was acquired.
A diffusion-weighted sequence was acquired with 63 direc-
tions (b = 1000 s/mm2, 7800ms repetition time, 90ms echo
time, 63 sequential interleaved ascending axial slices,
192  192 mm2 ﬁeld of view, 2mm slice thickness and
2  2mm2 in-plane resolution). For patients, we acquired dif-
fusion-weighted data once, usually on the ﬁrst session. Half of
patients’ diffusion data were collected on placebo, and half on
atomoxetine. LEDD did not correlate with fractional anisot-
ropy (Rae et al., 2012). Diffusion data were unavailable for
two control subjects.
Table 1 Demographic details of participants and clinical features of patients
Features / measures Parkinson’s disease Control Group difference
Number of males/females 13/6 10/10 ns
Age 69.38 (5.36) 67.40 (7.86) ns
Years of education 12.67 (2.44) 14.47 (3.09) ns
MMSE 28.50 (1.38) 29.30 (1.03) ns
Years of disease 9.79 (4.91) – –
UPDRS (‘ON’)
Mentation, behaviour and mood 3.16 (1.83) – –
Motor 25.87 (8.94) – –
Modified Hoehn and Yahr 2.26 (0.50) – –
Schwab and England Activities of Daily Living Scale 0.82 (0.15) – –
Levodopa equivalent daily dose 1080.16 (584.03) – –
Data are presented as (means, SD, and group differences). Group difference P-values refer to two-tailed t-tests or chi-squared (ns = not significant, P4 0.05 uncorrected). The
UPDRS motor subscale (part III) was assessed on both sessions, and the average presented here. The levodopa equivalent daily dose was estimated according to Tomlinson et al.
(2010).
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Functional MRI: preprocessing and
statistical modelling
Functional MRI preprocessing and analysis used SPM8
(r5236; www.ﬁl.ion.ucl.ac.uk/spm) with DCM10 (r5236) and
Automatic Analysis scripts (AA4, https://github.com/rhodricu
sack/automaticanalysis). Functional images were realigned to
the mean image and sinc interpolated in time to the middle
slice. The MPRAGE was co-registered to the mean functional
image, and segmented and normalized to the SPM MNI152
template. The normalization parameters were applied to func-
tional images, before smoothing with a Gaussian kernel of full-
width at half-maximum 8mm.
Single-subject ﬁrst-level general linear models were used to
model task events and moderator terms for DCM, while ac-
counting for experimental variance across the different trial
types. Events were modelled with 1 s duration, convolved
with the canonical haemodynamic response function. Go,
Stop-correct, Stop-incorrect, and NoGo-correct trials were pre-
sent for every subject. NoGo-incorrect, Go-error or Go-omis-
sion trials were modelled if the individual made incorrect
responses. The ﬁrst column of the design matrix included all
trial types. The second, third, and fourth regressors were para-
metric modulators of ‘all trials’ as follows: ‘stopping’, repre-
sented by Stop-correct4Go; ‘no-going’, represented by
NoGo-correct4Go; ‘stop accuracy’, represented by Stop-
correct4 Stop-incorrect. Serial orthogonalization was not
applied when estimating the ﬁrst-level general linear models.
Six nuisance regressors modelled subject movement as three
translations and three rotations.
To examine group effects, a second-level SPM analysis used
contrasts of interests from the ﬁrst level (Stop-correct4Go).
Group-level statistical maps were calculated for (i) controls; (ii)
Parkinson’s disease (PD)-placebo; and (iii) PD-atomoxetine,
with one-sample t-tests. Then, group differences between the
controls and PD-placebo (‘disease effect’, including also the
effect of dopaminergic medication and placebo medication)
were examined using two-sample t-tests. To examine the
effect of atomoxetine, we compared within-group differences
between PD-placebo and PD-atomoxetine sessions using a re-
peated-measures general linear model (‘atomoxetine effect’).
Contrasts were corrected for multiple comparisons with clus-
ter-based false discovery rate at P50.05 (FDRc, Chumbley
and Friston, 2009) or at an exploratory threshold P5 0.001
uncorrected, with 450 voxels per cluster. Local maxima are
listed in Supplementary Table 2.
Dynamic causal modelling
Dynamic causal modelling is a hypothesis-driven method to
quantify directional inﬂuences among brain regions (Friston
et al., 2003), inverting a set of biologically plausible generative
brain network models to the observed data (Stephan et al.,
2010). For each model, the free energy estimate of the log-
evidence (F) provides a measure of model accuracy adjusted
for complexity (Stephan et al., 2010).
To assess the response inhibition network we inverted the 20
models from Rae et al. (2015). These varied the interactions
between the inferior frontal gyrus, preSMA, subthalamic nu-
cleus and motor cortex. We selected these regions given their
essential contributions to action stopping (Chambers et al.,
2006; Aron et al., 2014; Rae et al., 2015), and their dysfunc-
tion during action control in Parkinson’s disease (Rowe et al.,
2010; Ray et al., 2012; Ye et al., 2015). We estimated con-
nectivity between brain regions in terms of (i) the ‘average’
connectivity as a function of external task-based perturbation
on all trials. This is a weighted average across different event
types (DCM.A matrix), sometimes known as baseline, ﬁxed or
the average connectivity (Stephan et al., 2008; Rowe et al.,
2010; Rae et al., 2015); (ii) the modulatory inﬂuences on con-
nections associated with successfully stopping an action
(DCM.B matrix in bilinear models) or activity in other regions
(DCM.D matrix, non-linear models only); and (iii) inputs that
drive network activity (DCM.C matrix, on ‘all trials’).
To model connectivity, we extracted the ﬁrst eigenvariate of
functional MRI time series in 5-mm spheres from each sub-
ject’s F-map, in left primary motor cortex (M1), subthalamic
nucleus, preSMA, and right inferior frontal gyrus. F-maps were
thresholded at P5 0.05 to identify the local maximum closest
to the group peak that also conformed to appropriate regional
anatomy. The group peak coordinates were deﬁned from a
second-level analysis including control and PD-placebo session
data using a one-sample t-test of ‘all trials’ for primary motor
cortex (x 38, y 20, z 60), and a one-sample t-test of ‘stop-
ping’ for preSMA (x 8, y 16, z 56) and right inferior frontal
gyrus (x 46, y 16, z 28). The right inferior frontal gyrus peak
was used due to right hemisphere lateralization in response
inhibition tasks (Aron et al., 2014; Rae et al., 2014), and
greater right inferior frontal gyrus activation during stopping
at the second-level in both patients and controls. The subtha-
lamic nucleus region of interest used a mask from the prob-
abilistic maps from Forstmann et al. (2012): 57 voxels of
2mm3 (Rae et al., 2015).
The 20 models comprised four ‘families’. Families differed
ﬁrst according to their weighted average connectivity (DCM.A)
between inferior frontal gyrus and preSMA, which could be
absent, unidirectional, or bidirectional (Fig. 2). This variation
in model structure permits inference on how the inferior fron-
tal gyrus and preSMA interact during stopping. Second, we
varied the modulatory effect of action stopping, which repre-
sented successful stopping (parametric modulator Stop-
correct4Go: Fig. 2). Dynamic causal models can be ‘linear’
(Friston et al., 2003) or ‘non-linear’ (Stephan et al., 2008). We
compared 12 linear models, in which successful stopping dir-
ectly modulated the strength of connectivity between brain
regions (DCM.B). We also compared eight non-linear
models, in which a frontal region (e.g. preSMA) served as
the modulatory inﬂuence of connectivity between two other
regions, thereby gating connectivity to the subthalamic nuclei
from the other prefrontal region (DCM.D). DCM includes
condition-speciﬁc inputs that drive the network dynamics.
Driving inputs were applied to both the inferior frontal
gyrus and preSMA (Fig. 2). Models were inverted using
DCM10 (r5236) with default prior distributions for haemo-
dynamic and coupling parameters, Gaussian error terms, and
liberal prior variances on self-connections (permitting a broad
range of neuronal transients up to several seconds), connection
parameters (reducing the probability of excursions into un-
stable domains of parameters space during optimization) and
hyperparameters. These match typical evoked neurophysio-
logical responses and our task design of short discrete events
support accurate estimation of connection strengths over a
wide range of observation noise (Friston et al., 2003).
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We compared model evidences to identify the most likely
causal model of the observed functional MRI data for con-
trols, PD-placebo, and PD-atomoxetine. We used Random
Effects and Fixed Effects Bayesian Model Selection with uni-
form priors over model space (Bayesian Model Selection,
Stephan et al., 2009a). By convention, a difference F4 5,
equivalent to a Bayes factor of 150, is considered very
strong evidence for the more likely model (Kass and Raftery,
1995). The Random Effects method estimates the exceedance
probability (XP), which represents the probability that a given
model is more likely than any other model to have generated
the observed data, under the assumption that subjects may
have generated data according to different generative networks
(Stephan et al., 2009a). In addition, the protected exceedance
probability (Rigoux et al., 2014) quantiﬁes the likelihood that
any model is more frequent than the others, above and beyond
chance (Table 2). The Fixed Effects analysis provides the pos-
terior model probability, which represents the probability that
a given model generated the observed group data (ranging
from 0 to 1), assuming that data are generated from a
common model for a group. It is potentially vulnerable to an
extreme outlier’s inﬂuence on the group inference. One patient
had a DCM.D parameter value 42 standard deviations (SD)
from the group mean on the placebo session. We repeated
model selection without this patient. There was a negligible
change in the difference in F between the ﬁrst and second
most likely models (4.11 to 4.16).
In a three-step hierarchical model selection procedure (Fig.
3), we ﬁrst compared the 12 linear models to the eight non-
linear models. With evidence in favour of the non-linear
models (Table 2), we next compared the non-linear inferior
frontal gyrus models to the preSMA models. Finally we com-
pared the four non-linear preSMA models according to their
average connectivity ‘family’ status (Fig. 2).
When the exceedance probability does not exceed 0.9, it is
recommended to average all models with a probability of
40.05 (Penny et al., 2010). This being the case for the PD-
placebo and PD-atomoxetine sessions, we used Bayesian
Model Averaging over the four non-linear preSMA models,
and examined the averaged model parameters in terms of in-
dividual patient differences in disease severity and drug level.
Individual differences in frontal-
subcortical connectivity
Individual differences in functional connectivity are inﬂuenced
by structural connectivity (Rae et al., 2015) and neurotrans-
mitter levels (Stephan et al., 2009b). We therefore tested
whether disease severity and blood plasma levels of atomox-
etine inﬂuence functional connectivity.
For each patient, we examined the averaged model connect-
ivity parameters from the four non-linear preSMA models. The
difference in parameters indicates the change in frontal-subcor-
tical connectivity due to the drug (counterbalancing session
order effects). Change in connectivity values (ATO-PLA)
were used as dependent variables in multiple regression
models (SPSS), for (i) ‘ inferior frontal gyrus to subthalamic
nucleus connectivity’; and (ii) ‘ preSMA non-linear modula-
tion’. We selected these two variables of interest as they rep-
resent the cortical inputs to the subthalamic nucleus. The
independent variables in the regression models were Uniﬁed
Parkinson’s Disease Rating Scale (UPDRS)-III (as a measure
of disease severity) and blood plasma drug level (ng/ml).
Pulsed arterial spin labelling:
preprocessing and statistical
modelling
Pulsed arterial spin labelling time series were converted to cere-
bral blood ﬂow maps using ASLtbx (https://cfn.upenn.edu/
zewang/ASLtbx.php). Following rigid-body alignment,
images were smoothed with a Gaussian kernel of full-width
at half-maximum 8mm. Cerebral blood ﬂow quantiﬁcation
used simple subtraction and the mean M0 signal from CSF
in ventricle regions of interest for quantiﬁcation. Cerebral
blood ﬂow was compared between the PD-placebo and PD-
atomoxetine sessions using a whole-brain voxelwise analysis in
SPM12b with a repeated measures t-test, corrected for multiple
comparisons with family-wise error (FWE) at P5 0.05 and at
the exploratory threshold P5 0.001 (uncorrected).
Diffusion MRI
We used whole-brain tract-based spatial statistics (TBSS, Smith
et al., 2006) to examine correlations between fractional anisot-
ropy and the difference in SSRT between placebo and atomox-
etine sessions (SSRT), complementing the analysis of
functional connectivity. Using FSL 4.1.8 (www.fmrib.ox.ac.
uk/fsl), diffusion images were corrected for head movements
and eddy currents then smoothed with a 2.5mm Gaussian
kernel, before ﬁtting diffusion tensors. In tract-based spatial
statistics, subjects’ fractional anisotropy maps were registered
to the most representative subject, and normalized to MNI152
space. A mean fractional anisotropy skeleton was created and
thresholded at fractional anisotropy40.25. Using FSL ‘ran-
domise’, 10 000 permutations with Threshold-Free Cluster
Enhancement (TFCE, Smith and Nichols, 2009) tested for cor-
relations between fractional anisotropy and SSRT across the
mean fractional anisotropy skeleton. In the design matrix, add-
itional columns containing control SSRT, patient age, control
age, UPDRS, and LEDD were entered as covariates. We also
tested for correlations between fractional anisotropy and
LEDD. In three separate design matrices, we tested for correl-
ations between fractional anisotropy and the three DCM par-
ameters representing the combined effect of the non-linear
frontal input to the subthalamic nucleus (DCM.A preSMA to
inferior frontal gyrus, DCM.A inferior frontal gyrus to sub-
thalamic nucleus, and DCM.D modulation), in the most likely
model for (i) controls; (ii) PD-placebo; and (iii) PD-atomoxe-
tine. All variables were demeaned. Voxels with signiﬁcant cor-
relation between fractional anisotropy and SSRT were back-
projected to native space using FSL ‘deproject’.
Results
Behavioural performance
Patients were impaired on the stop-signal task, with longer
SSRTs on placebo (224ms) than healthy controls (171ms,
t = 2.758, P = 0.009). Atomoxetine did not signiﬁcantly
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alter the group average SSRT (228ms, t = 0.305,
P = 0.764) in line with previous studies (Ye et al., 2015).
However, the non-signiﬁcant group effect obscures signiﬁ-
cant individual differences related to disease severity, neural
structure and function. The baseline (placebo) SSRT corre-
lated (r = 0.757, P5 0.001) with change in SSRT on
atomoxetine (i.e. SSRT-placebo SSRT-atomoxetine), indi-
cating that ‘baseline’ SSRT was predictive of the extent to
which patients improved on the drug (Fig. 4A).
Univariate functional MRI of success-
ful response inhibition:
Stop-correct4Go
Figure 1A conﬁrms that the healthy controls have activation
of the right inferior frontal gyrus, bilateral preSMA, and
bilateral caudate nucleus. Patients with Parkinson’s disease
also show activation of these regions (Fig. 1B), albeit to a
lesser degree: the comparison of controls versus PD-placebo
(‘disease effect’) conﬁrms signiﬁcant underactivation of the
right inferior frontal gyrus, preSMA, putamen and posterior
caudate nucleus (Fig. 1D). The group difference in the sub-
thalamic nucleus was signiﬁcant using a small volume cor-
rection from the subthalamic nucleus map (P5 0.05 FWE,
peak local maxima x 8, y 16, z 8).
On atomoxetine, patients showed activation of the right
inferior frontal gyrus and bilateral preSMA (Fig. 1C).
Although preSMA activation was not present in PD-pla-
cebo (Fig. 1B), a within-group contrast comparing PD-pla-
cebo versus PD-atomoxetine (‘atomoxetine effect’) did not
show a signiﬁcant difference (P4 0.05, FDRc). The
Table 2 Summary of model comparisons
Group Comparison XP pXP BOR
Controls Linear 0.0003 N/A
Non-linear 0.9997
IFG stopping input 0.1574 N/A
PreSMA stopping input 0.8426
NAp 0.0116 0.0223 0.04
NBp 0.0423 0.0516
NCp 0.9459 0.9146
NDp 0.0002 0.0114
PD-placebo Linear 0.0765 N/A
Non-linear 0.9235
IFG stopping input 0.0129 N/A
PreSMA stopping input 0.9871
NAp 0.6281 0.4175 0.56
NBp 0.1641 0.2119
NCp 0.2054 0.2302
NDp 0.0024 0.1403
PD-atomoxetine Linear 0.1350 N/A
Non-linear 0.8650
IFG stopping input 0.1234 N/A
preSMA stopping input 0.8766
NAp 0.4450 0.3365 0.56
NBp 0.1487 0.2050
NCp 0.4033 0.3180
NDp 0.0030 0.1404
Exceedance probabilities (XP) from the three-step hierarchical model selection,
comparing (i) linear versus non-linear models; (ii) non-linear inferior frontal gyrus
versus preSMA models; (iii) the four non-linear preSMA models with different average
connectivity ‘family’ status. The protected exceedance probabilities (pXP) show that
for the patient sessions, no model is more frequent than any others, above and beyond
chance, reflecting the presence of marked patient heterogeneity in response to drug
(Fig. 4). BOR = Bayesian Omnibus Risk.
Figure 1 Stopping activations (Stop-correct`Go). (A)
Controls; (B) PD-placebo; (C) PD-atomoxetine (ATO); (D)
controls4 PD-placebo (PLA, ‘disease effect’); and (E) PD-
atomoxetine4 PD-placebo (‘drug effect’). (A–D) Shown at
P5 0.05 FDR-cluster corrected; (E) shown at P5 0.001 uncor-
rected with minimum 50 voxels per cluster (no significant clusters at
P5 0.05, FDRc). Note that the ‘disease effect’ incorporates the
presence of Parkinson’s disease, the use of usual dopaminergic
medications in patients (but not in controls), and the session-
specific use of a placebo tablet. The ‘drug effect’ refers only to the
main effect of atomoxetine, which may obscure significant individual
patient differences in regional brain activations.
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exploratory threshold (P5 0.001) revealed activation in the
left striatum on atomoxetine (Fig. 1E). Supplementary
Table 1 reports local maxima for each contrast. Although
atomoxetine had only modest effects on activation within
regions, this does not imply a lack of effect on coupling
between regions, the principal focus of this study to which
we turn next.
Structure and connectivity of the
stopping network
Twenty models examined interactions among the inferior
frontal gyrus, preSMA, subthalamic nucleus, and primary
motor cortex during response inhibition (Fig. 2). Bayesian
model selection (Stephan et al., 2009a) compared these re-
sponse inhibition network models separately for (i) con-
trols; (ii) PD-placebo; and (iii) PD-atomoxetine (Fig. 3
and Supplementary Fig. 1). In a hierarchical model selec-
tion (Fig. 3), for all groups, evidence for the non-linear
models outweighed evidence for the linear models, and
for the non-linear preSMA models over the inferior frontal
gyrus models (Table 2). The addition of a driving input of
‘Stop-correct4Go’ to inferior frontal gyrus or preSMA in
the linear models (as exists in the non-linear models) was
associated with lower model evidences (not shown).
In controls, amongst the four non-linear preSMA models,
the most likely was model NCp (exceedance P40.9 and
protected exceedance P40.9). In this model, successful stop-
ping modulates activity of the preSMA, which gates the
strength of inputs from the inferior frontal gyrus to the sub-
thalamic nucleus. In addition to this non-linear modulation,
there is a direct cortico-cortical inﬂuence from the preSMA to
the inferior frontal gyrus (see Family C, Fig. 2).
In PD-placebo and PD-atomoxetine, no single model had
an exceedance probability4 0.9, which may be due to het-
erogeneity in the patient group. Comparing all 20 models
(Supplementary Fig. 1), the numerically most likely models
in terms of exceedance probability were model NAp for
PD-placebo, and model NCp (c.f. controls) for PD-atomox-
etine. This is weak evidence, but consistent with the inter-
pretation that in some patients with Parkinson’s disease on
placebo (plus their usual dopaminergic medication), the dif-
ference to healthy controls lies in the absence of the cortical
interaction from the preSMA to the inferior frontal gyrus
(Family A, Fig. 2), while atomoxetine restored the most
likely model to that observed in healthy controls, including
the cortical interaction from the preSMA to the inferior
frontal gyrus (Family C, Fig. 2).
At the group level there was no overall most likely model
for either PD-placebo or PD-atomoxetine sessions (excee-
dance P50.9 and protected exceedance P50.9). This is
consistent with the presence of subgroups of patients in a
separate cohort as observed by Ye et al. (2015, 2016): on
the placebo session, some patients exhibit a response inhib-
ition network similar to that of controls, while others are
missing the key cortico-cortical interaction within the net-
work, and are so placed to beneﬁt from the effect of ato-
moxetine. This highlights the impact of individual patient
differences on neural and behavioural responses to atomox-
etine. Accordingly, when there is no overall most likely
model, we used Bayesian Model Averaging over the four
non-linear preSMA models (Penny et al., 2010; Stephan
Figure 2 The 20 causal models. Each represents alternative hypotheses of frontal-subcortical interactions during response inhibition (from
Rae et al., 2015). We compared which of these models was most likely for controls, PD-placebo, and PD-atomoxetine (see Fig. 3). The inset panel
shows the schematic arrangement of the four model regions [preSMA, inferior frontal gyrus (IFG), subthalamic nucleus (STN), M1] in each of the
20 models. In ‘linear’ models, successful stopping modulates the strength of connectivity between brain regions. In ‘non-linear’ models, stopping
modulates activity of one region (e.g. preSMA), which gates the strength of connectivity from the other frontal region (e.g. inferior frontal gyrus)
to the subthalamic nucleus. Dotted arrows indicate the location of the modulatory effect of stopping in each model. Solid arrows indicate
exogenous driving inputs of all task trials. Model ‘families’ (A–D) share average connectivity patterns between the two frontal regions (preSMA
and inferior frontal gyrus).
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et al., 2010), and extracted the model parameters to test for
relationship with disease severity and plasma drug level.
To illuminate why the NAp and NCp models are the
most likely in terms of their features, we examined the
parameter conditional probabilities (DCM.Pp), after
Bayesian Parameter Averaging across the subjects in each
group. These represent the probability that a parameter has
a non-zero value (05P51). Two parameters showed a
clear difference across groups: (i) the preSMA to inferior
frontal gyrus connection had a conditional probability of
0.99 in controls, and 0.94 in PD-atomoxetine, but was not
present in PD-placebo (this is the connection restored by
atomoxetine in a subset of patients according to Bayesian
Model Selection); and (ii) the conditional probability of the
stopping input to preSMA was 0.97 in controls, and 0.99
in PD-atomoxetine, but 0.57 in PD-placebo.
Individual differences in frontal-
subcortical connectivity
We used multiple regressions to test how disease severity
and drug level inﬂuence frontal-subcortical connectivity.
We examined the change in connectivity values (ATO-
PLA) between PD-placebo and PD-atomoxetine in the con-
nectivity parameters from Bayesian Model Averaging of the
four non-linear preSMA models. Disease severity (UPDRS)
and drug level were entered as independent variables in
multiple regression models with (i) ‘ inferior frontal
gyrus to subthalamic nucleus connectivity’ (DCM.A); and
(ii) ‘ preSMA non-linear modulation’ (DCM.D) as de-
pendent variables. In the ﬁrst model the UPDRS was
related to the change in connectivity (b = 0.535, t = 2.419,
P = 0.028; Pearson r = 0.561, P = 0.006), indicating that the
Figure 3 Bayesian model selection. Model evidences were compared across the 20 models (see Fig. 2) for (A) controls, (B) PD-placebo,
and (C) PD-atomoxetine. In a three-step hierarchical model selection, the 12 linear models were first compared to the eight non-linear models.
With evidence in favour of the non-linear models (Table 2), we next compared the non-linear inferior frontal gyrus models to the non-linear
preSMA models. Finally we compared the four non-linear preSMA models according to their average connectivity ‘family’ status (see Fig. 2, and
Table 2 for BOR and pXP values). Displayed to the right, for each group the model parameters are shown after Bayesian Model Averaging across
the four non-linear preSMA models. Labels on the x-axis indicate the identity of the models as for Fig. 2: N = non-linear; A to D = model families.
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greater the disease severity, the greater the change in fron-
tal-subcortical connectivity with atomoxetine (Fig. 4B). In
the second model the drug level correlated with change in
preSMA modulation (b = 0.443, t = 1.817, P = 0.088;
Pearson r = 0.398, P = 0.046), suggesting that the higher
blood plasma levels of atomoxetine, the greater the
change in modulation of frontal-subcortical connectivity
by the preSMA (Fig. 4C).
Perfusion and haemodynamics
A repeated-measures ANOVA comparing pulsed arterial
spin labelling measures of cerebral blood ﬂow between
the PD-placebo and PD-atomoxetine sessions showed no
effects of atomoxetine on local perfusion at corrected or
uncorrected thresholds. This suggests that changes in acti-
vation and connectivity were more likely to be due to an
effect of atomoxetine on neuronal interactions, rather than
on perfusion. The haemodynamic parameters estimated by
DCM model inversion provide an alternative means to
assess the potential impact of drug on neurovascular re-
sponses. In a repeated-measures ANOVA, the estimated
transit, decay and epsilon parameters of the haemodynamic
balloon model did not differ between placebo and atomox-
etine sessions (F5 1).
Diffusion MRI
Tract-based spatial statistics conﬁrmed a signiﬁcant correl-
ation between change in SSRT on atomoxetine (versus pla-
cebo) and fractional anisotropy in white matter underlying
the inferior frontal gyrus and external capsule (P5 0.05
TFCE corrected, Fig. 5). At a lower threshold (P5 0.055
TFCE corrected), there was a trend correlation between
fractional anisotropy and change in SSRT in the internal
capsule, which carries interactions between frontal cortex
and subcortical nuclei, previously shown to be abnormal in
Parkinson’s disease (Rae et al., 2012; Ye et al., 2015).
These results conﬁrm that white matter structure in
frontal-subcortical pathways inﬂuences the degree of behav-
ioural change in response to atomoxetine (Ye et al., 2015).
In separate permutation analyses, we tested for correl-
ations between fractional anisotropy and the three DCM
parameters representing the combined effect of the non-
linear frontal input to the subthalamic nucleus (DCM.A
preSMA to inferior frontal gyrus, DCM.A inferior frontal
gyrus to subthalamic nucleus, and DCM.D modulation).
None of these showed signiﬁcant (P5 0.05 TFCE) correl-
ations between fractional anisotropy and DCM parameters.
Discussion
In Parkinson’s disease, the ability to stop actions is im-
paired, together with abnormal connectivity in the response
inhibition network. We found that atomoxetine can en-
hance the interaction between the preSMA and inferior
Figure 4 Correlations between behaviour, UPDRS, drug level, and connectivity on atomoxetine. (A) Correlation between
‘baseline’ SSRT on placebo, and change in SSRT on atomoxetine (Pearson correlation, r = 0.757, P5 0.001). (B) Correlation between UPDRS
(part III, motor subscale averaged across sessions), and the change caused by atomoxetine () in connectivity from inferior frontal gyrus to
subthalamic nucleus (DCM.A matrix), after Bayesian Model Averaging (Pearson correlation, r = 0.561, P = 0.006). (C) Correlation between plasma
drug level (ng/ml), and change in non-linear modulation of inferior frontal gyrus to subthalamic nucleus connectivity by the preSMA (DCM.D
matrix), after Bayesian Model Averaging (Pearson correlation, r = 0.398, P = 0.046).
Figure 5 White matter structure correlates with response
inhibition. The change in stopping efficiency (SSRT) between
PD-placebo and PD-atomoxetine sessions correlates with fractional
anisotropy in white matter underneath the inferior frontal gyrus and
in the external capsule (P5 0.05 TFCE corrected).
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frontal gyrus, two regions that act together to inﬂuence the
subthalamic nucleus for successful response inhibition.
Moreover, atomoxetine increased the efﬁciency of stopping
(SSRT) in proportion to structural connectivity of white
matter likely carrying interactions between frontal cortex
and the subthalamic nuclei. This network approach builds
on prior reports of atomoxetine’s inﬂuence on regional ac-
tivation (Ye et al., 2015), conﬁrming the importance of
disease severity and drug levels such that atomoxetine
only changes connectivity and improves performance in a
subset of patients (Kehagia et al., 2014; Ye et al., 2015,
2016). When atomoxetine does improve response inhib-
ition, it does so with enhanced functional network
connectivity: the effect is more likely in people with
poorer baseline inhibitory control who have an optimum
drug level, moderately severe disease and ‘relatively’ intact
white matter.
The response inhibition network in
Parkinson’s disease
Interactions between the preSMA, inferior frontal gyrus,
and their projections to the subthalamic nucleus are critical
for response inhibition (Aron et al., 2003; Chambers et al.,
2006; Frank et al., 2007; Ballanger et al., 2009; Duann
et al., 2009; Forstmann et al., 2012; Rae et al., 2015).
Multi-stage pathways between these regions underpin the
control of action, through direct, indirect, and hyperdirect
routes (Nambu et al., 2002; Redgrave et al., 2010; Wiecki
and Frank, 2013).
Patients differed from controls in the inﬂuence of
preSMA on the inferior frontal gyrus: in some patients,
this input was missing, but restored by atomoxetine. The
relevance of this connection to model selection is suggested
by the conditional probabilities in both Random Effects
and Fixed Effects comparisons (the DCM.Pp values).
These also accord with the univariate analyses in Fig. 1,
such as reduced activation of preSMA in patients on pla-
cebo. However, model comparison should properly be
made on the evidence for the whole model, because of po-
tential covariances among parameters (Rowe et al., 2010).
In older adults, as in younger adults (Rae et al., 2015),
these areas interacted in the inﬂuence of their projections to
the subthalamic nucleus, to successfully stop an action. The
non-linear interaction between subcortical projections of
the preSMA and inferior frontal gyrus on the subthalamic
nucleus differed between the elderly controls in this study
and that previously observed in healthy young adults (Rae
et al., 2015). However, the leading models here and in Rae
et al. (2015) shared the critical feature of the non-linear
interaction of the cortical projections to subthalamic nu-
cleus. These winning models are distinct from the models
embodying precedence of preSMA or inferior frontal gyrus
in the stopping process. We do not infer an effect of ageing
on the stopping network from these data: to resolve poten-
tial cohort effects other than age would require
epidemiological selection of old and young (Shafto et al.,
2014). Moreover, age would not explain the difference be-
tween groups in the current study, as patients were com-
pared to age-matched controls.
The subthalamic nucleus acts as a ‘brake’ on thalamocor-
tical outputs while the best course of action is determined
(Frank et al., 2007; Wiecki and Frank, 2013). Deep brain
stimulation at the subthalamic nucleus improves bradykine-
sia in Parkinson’s disease via stabilization of dysfunctional
cortico-subcortical oscillations. However, there is mixed
evidence for the impact of DBS on impulsivity (Ballanger
et al., 2009; Mirabella et al., 2012), which may not restore
a window of opportunity for this brake function in situ-
ations of response conﬂict (Frank et al., 2007). Together,
these data suggest the restorative effect of atomoxetine
occurs upstream of the basal ganglia, in the frontal
cortex (c.f. Borchert et al., 2016).
Our results suggest that atomoxetine exerts its effect at
the level of the inferior frontal gyrus, increasing sensitivity
to afferent inputs from the preSMA and activation on suc-
cessful stop trials. This interpretation is supported by the
anatomical distribution of a1- and a2-noradrenergic recep-
tors, and noradrenaline transporters, which are scarce in
the basal ganglia, but dense in frontal cortex (Logan
et al., 2007; Amunts et al., 2010).
Other neurotransmitter systems also modulate the effect-
ive connectivity in motor and inhibition networks. For
example, Herz et al. (2015) used DCM to show that dopa-
minergic treatment modulates the connectivity from puta-
men to motor cortex, including pathways via subthalamic
nucleus, during response inhibition trials. In addition, the
effect of serotonergic enhancement by citalopram depends
in part on the integrity of the anterior limb of the internal
capsule that contains the direct and indirect projections
from the frontal cortex to the subthalamic nucleus (Ye
et al., 2014). The effects of dopamine and serotonin were
increased in those with levodopa-induced dyskinesia or
more advanced disease, respectively. Combinations of nor-
adrenergic, dopaminergic and serotonergic approaches may
be clinically advantageous (Huot et al., 2015) at the ex-
pense of understanding the individual contribution of
each monoamine and links to preclinical models (Eagle
et al., 2008; Bari et al., 2011).
The impact of individual differences
Atomoxetine did not improve patients’ response inhibition
performance at the group level, in contrast to Kehagia et al.
(2014) but in keeping with Ye et al. (2015). In addition,
while there was a clear model comparison result in the
control group, there was evidence for subgroups of pa-
tients: on the placebo session, some patients exhibit a re-
sponse inhibition network similar to that of controls, while
others are missing the key cortico-cortical interaction
within the network, and so are placed to beneﬁt from the
effect of atomoxetine. This is highlighted by the Random
Effects model selection analysis applying protected
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exceedance probabilities (Rigoux et al., 2014) in which, at
the group level, one considers how likely it is that any
model is more frequent than the others, above and
beyond chance, in contexts in which there are potentially
differences in model parameters in a common network or
differences in the underlying network architecture between
subjects. For these reasons, we examined associations with
individual patient characteristics and changes in connectiv-
ity. Individual differences in Parkinson’s disease severity,
drug levels, and white matter structure of frontal-subcor-
tical tracts inﬂuence cognitive and behavioural dysfunction
including response inhibition (Chamberlain et al., 2007; Ye
et al., 2015). In our cohort, we conﬁrmed that disease se-
verity and drug plasma levels relate to frontal-subcortical
connectivity in response inhibition; and that structural fron-
tal-subcortical connectivity correlated with the effect of ato-
moxetine on performance (SSRT).
Diffusion tensor imaging reveals that the white matter
underlying the inferior frontal gyrus is abnormal in
Parkinson’s disease, including the tracts connecting frontal
cortex to the basal ganglia (Rae et al., 2012; Agosta et al.,
2013). This may relate to loss of axonal projections through
secondary degeneration, changes in myelin, or reduced
axonal calibre (Wheeler-Kingshott and Cercignani, 2009;
Rae et al., 2012). It means that enhancement of cortical
activity during response inhibition may be unable to exert
a behavioural effect because of functional disconnection
from the basal ganglia. The cortical inﬂuences on the sub-
thalamic nucleus are not absent, but the white matter change
is sufﬁcient to undermine drug efﬁcacy: the greater the frac-
tional anisotropy in the white matter underlying the inferior
frontal gyrus, the greater the change in SSRT between pla-
cebo and atomoxetine sessions.
We propose that patients with ‘relatively’ preserved white
matter are better able to transform cortical responses into
behaviour. Although both noradrenergic deﬁcits and ana-
tomical change are progressive, individual differences in the
rates at which these systems change inﬂuence behavioural
change and treatment response. There is a precedent for
this in dopaminergic systems, in which the dopaminergic
effects on function depends on cortico-subcortical anatom-
ical connectivity (van der Schaaf et al., 2013; van
Schouwenburg et al., 2013).
Individual differences in drug levels may result from gen-
etic variation in atomoxetine catabolism and variation in
the impact of Parkinson’s disease pathology on visceral and
digestive function (Goedert et al., 2013). It is important to
consider such individual differences when evaluating ato-
moxetine as a therapeutic tool, and look beyond the lack
of a whole-group change of behaviour. This also has im-
plications for the stratiﬁcation of heterogeneous patients in
clinical trials.
Mechanisms of action
We studied patients on their normal regimen of dopamin-
ergic medication (i.e. in their ‘ON’ state). We did not
examine the ‘OFF’ state as we anticipate that future nora-
drenergic therapies would be used in the context of dopa-
minergic therapy not instead of it. Although we emphasize
the role of noradrenaline in response inhibition (Eagle and
Baunez, 2010; Bari and Robbins, 2013), dopamine also
inﬂuences impulsivity and the control of action (Hughes
et al., 2010, 2013; Cummins et al., 2012; Nandam et al.,
2013; Cubillo et al., 2014; Napier et al., 2014). Despite
highly selective binding to noradrenaline transporters, ato-
moxetine might also increase extracellular cortical dopa-
mine (Bymaster et al., 2002), by blocking reuptake of
dopamine via the noradrenaline transporter (Yamamoto
and Novotney, 1998). However, in contrast to the dual-
action of methylphenidate, the effect of atomoxetine on
noradrenaline is much greater than on dopamine
(Bymaster et al., 2002). Moreover, levodopa has little in-
ﬂuence on SSRT in Parkinson’s disease (Obeso et al.,
2011b) or preclinical models.
Levodopa and dopamine agonists have been associated
with impulse control disorders, such as pathological gam-
bling, hypersexuality and binge eating (Voon et al., 2009;
Napier et al., 2014). Currently, the main strategy to treat
impulse control disorders is to reduce dopaminergic medi-
cation. However, impulsivity and poor response inhibition
are common even in the absence of impulse control dis-
orders (Nombela et al., 2014a) and can occur before dopa-
minergic therapy. We speculate that the effects of
atomoxetine are not mediated primarily by a dopaminergic
mechanism, but that atomoxetine might facilitate other
approaches to treating impulsivity, enhancing response in-
hibition, and more conservative approaches to risk-taking
(Kehagia et al., 2014).
Indirect effects of atomoxetine must also be considered,
including modulation of the neurovascular coupling
(Iannetti and Wise, 2007). Therefore we used perfusion
arterial spin labelling, but did not ﬁnd a signiﬁcant effect
on perfusion. It is important to note that DCM optimizes
the neurovascular response function as part of model inver-
sion, and accommodates session speciﬁc variations in the
haemodynamic response. In our implementation of DCM,
we used default priors for haemodynamic and coupling
parameters in keeping with previous clinical applications
in Parkinson’s disease (Rowe et al., 2010; Kahan et al.,
2014; Michely et al., 2015). There may be grounds to
adjust these priors if, for example, pulsed arterial spin
labelling indicates an altered vascular response, or when
studying extreme outlier neurophysiological states (Gilbert
et al., 2016). However, the posterior parameters of the
‘balloon model’ of haemodynamic responses did not differ
between drug sessions, consistent with a lack of effect of
noradrenaline infusion on human cerebral blood ﬂow and
reactivity (Moppett et al., 2008).
The model inversion and model selection procedures, in
which model selection is weighted by the subjects’ model
precision, provide replicable inferences of causal (direc-
tional) interactions between brain regions (Rowe, 2010;
Friston et al., 2013). This underlies the widespread use of
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DCM to study changes in functional network dynamics
from disease (Rowe et al., 2010; Kahan et al., 2014;
Michely et al., 2015), remission (Goulden et al., 2012),
and treatment (Wang et al., 2011; Herz et al., 2015).
Although DCM has been validated using functional MRI
combined with invasive recordings in animals (David et al.,
2008), it is also useful to seek corroboration from other
methods. For example, DCM connectivity parameters cor-
relate with neurophysiological measures using transcranial
magnetic stimulation (Boudrias et al., 2012), and correlate
with brain structure and function (Song et al., 2013; Rae
et al., 2015). Here, the effects of both white matter struc-
ture and functional connectivity on behaviour support our
DCM inferences.
Despite the advantages of DCM, it does not distinguish
between mono- and polysynaptic pathways. Therefore, one
cannot determine whether the interaction between preSMA
and inferior frontal gyrus is via direct cortico-cortical path-
ways or through a subcortical pathway (Coxon et al., 2012;
Forstmann et al., 2012; Rae et al., 2015). The thalamus,
striatum, and globus pallidus are also relevant to response
inhibition (Nambu et al., 2002; Redgrave et al., 2010;
Wiecki and Frank, 2013) and our models implicitly incorp-
orate these subcortical stage posts. However, we did not
delineate these stage posts, focusing instead on four brain
regions that were necessary and sufﬁcient to test our hypoth-
eses (Chamberlain et al., 2007; Cubillo et al., 2014; Ye et al.,
2015). This method also guards against a computational ex-
plosion of unnecessary models, and balances model complex-
ity and generalizability (Stephan et al., 2010). Future studies
however could explore further the modulation of activity
within the direct, indirect, and hyperdirect pathways.
This study highlights the potential utility for atomoxetine
as an adjunctive therapy in Parkinson’s disease, if stratiﬁed
in light of the patient differences that inﬂuence its behav-
ioural beneﬁt. However, we studied an acute single dose of
atomoxetine, in order to explore its effects on underlying
neural mechanisms of a task that provides a direct link to
preclinical studies of the neural basis of impulsivity. Clinical
doses of atomoxetine may be higher, and used chronically
(Clemow, 2014). Indeed, chronic atomoxetine up to 100mg
is well-tolerated in Parkinson’s disease (Marsh et al., 2009).
Future patient studies in larger cohorts may also wish to
consider the impact of genetic variations on response inhib-
ition ability (Cummins et al., 2012), or other imaging mar-
kers of cognition in Parkinson’s disease (Nombela et al.,
2014b). For example, polymorphism of the noradrenaline
transporter affects inferior frontal gyrus activation and be-
haviour in the stop-signal task (Whelan et al., 2012).
Conclusions
The analysis of brain network interactions provides mechan-
istic insights into noradrenergic inﬂuences on behaviour in
Parkinson’s disease. We provide a replication of the potential
for atomoxetine to improve response inhibition in some, but
not all cases, according to variations in baseline performance,
disease severity, drug level andwhite matter structure. In add-
ition, we provide evidence that atomoxetine modulates cor-
tico-cortical functional connectivity in Parkinson’s disease,
subject to individual patient differences. These factors validate
preclinical models of disease, executive function and impul-
sivity. They also highlight the need for stratiﬁcation in clinical
trials of noradrenergic therapy, as an adjunct to dopaminergic
therapy, so as to direct noradrenergic treatment to the subset
of patients who are most likely to beneﬁt.
Acknowledgements
We thank Tibor Auer for assistance with programming,
and Marta Correia for advice on diffusion-weighted ima-
ging analysis.
Funding
This work was primarily funded by the Wellcome Trust
(103838) with additional support from the Medical Research
Council (MC-A060-5PQ30, and RG62761), the NIHR
Cambridge Biomedical Research Centre, Parkinson’s UK and
the James F McDonnell Foundation. The BCNI is supported
by the Wellcome Trust and Medical Research Council.
Conflicts of interest
Professor Sahakian reported receiving consulting fees for
Cambridge Cognition, Servier, Otsuka, and Lundbeck,
grants from Janssen/Johnson & Johnson, and share options
in Cambridge Cognition. Professor Barker reported pay-
ment from Wiley for a basic textbook for Neuroscience.
Professor Robbins reported receiving consulting fees from
Cambridge Cognition, Lilly, Merck, Lundbeck, GSK, Teva
and Shire, grants from GSK, Lilly and Lundbeck, and pay-
ments from Cambridge Cognition for ‘CANTAB’, and hon-
orarium from Springer-Verlag for editorial duties for
‘Psychopharmacology’. Professor Rowe reported receiving
consulting fees from Lilly, grants from the Wellcome
Trust, NIHR Biomedical Research Centre, the James F
McDonnell Foundation, the Medical Research Council,
and AZ Medimmune.
Supplementary material
Supplementary material is available at Brain online.
References
Agosta F, Kostic VS, Davidovic K, Kresojevic N, Sarro L, Svetel M,
et al. White matter abnormalities in Parkinson’s disease patients
with glucocerebrosidase gene mutations. Mov Disord 2013; 28:
772–8.
2246 | BRAIN 2016: 139; 2235–2248 C. L. Rae et al.
 by guest on A
ugust 10, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
Amunts K, Lenzen M, Friederici AD, Schleicher A, Morosan P,
Palomero-Gallagher N, et al. Broca’s region: novel organizational
principles and multiple receptor mapping. PLoS Biol 2010;8:
e1000489.
Aron AR, Fletcher PC, Bullmore ET, Sahakian BJ, Robbins TW. Stop-
signal inhibition disrupted by damage to right inferior frontal gyrus
in humans. Nat Neurosci 2003; 6: 115–6.
Aron AR, Robbins TW, Poldrack RA. Inhibition and the right inferior
frontal cortex: one decade on. Trends Cogn Sci 2014; 18: 177–85.
Ballanger B, van Eimeren T, Moro E, Lozano AM, Hamani C,
Boulinguez P, et al. Stimulation of the subthalamic nucleus and im-
pulsivity: release your horses. Ann Neurol 2009; 66: 817–24.
Bari A, Mar AC, Theobald DE, Elands SA, Oganya KC, Eagle DM,
et al. Prefrontal and monoaminergic contributions to stop-signal
task performance in rats. J Neurosci 2011; 31: 9254–63.
Bari A, Robbins TW. Noradrenergic versus dopaminergic modulation
of impulsivity, attention and monitoring behaviour in rats perform-
ing the stop-signal task: possible relevance to ADHD.
Psychopharmacology 2013; 230: 89–111.
Borchert RJ, Rittman T, Passamonti L, Ye Z, Sami S, Jones SP, et al.
Atomoxetine enhances connectivity of prefrontal networks in
Parkinson’s disease. Neuropsychopharmacology 2016; 41: 2171–7.
Boudrias MH, Goncalves CS, Penny WD, Park CH, Rossiter HE,
Talelli P, et al. Age-related changes in causal interactions between
cortical motor regions during hand grip. Neuroimage 2012; 59:
3398–405.
Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld
PG, Heiligenstein JH, et al. Atomoxetine increases extracellular
levels of norepinephrine and dopamine in prefrontal cortex of rat:
a potential mechanism for efﬁcacy in attention deﬁcit/hyperactivity
disorder. Neuropsychopharmacology 2002; 27: 699–711.
Chamberlain SR, Del Campo N, Dowson J, Muller U, Clark L,
Robbins TW, et al. Atomoxetine improved response inhibition in
adults with attention deﬁcit/hyperactivity disorder. Biol Psychiatry
2007; 62: 977–84.
Chamberlain SR, Hampshire A, Muller U, Rubia K, Del Campo N,
Craig K, et al. Atomoxetine modulates right inferior frontal activa-
tion during inhibitory control: a pharmacological functional mag-
netic resonance imaging study. Biol Psychiatry 2009; 65: 550–5.
Chambers CD, Bellgrove MA, Stokes MG, Henderson TR, Garavan
H, Robertson IH, et al. Executive “brake failure” following deacti-
vation of human frontal lobe. J Cogn Neurosci 2006; 18: 444–55.
Chumbley JR, Friston KJ. False discovery rate revisited: FDR and
topological inference using Gaussian random ﬁelds. Neuroimage
2009; 44: 62–70.
Clemow DB. Suboptimal dosing of Strattera (atomoxetine) for ADHD
patients. Postgrad Med 2014; 126: 196–8.
Coxon JP, Van Impe A, Wenderoth N, Swinnen SP. Aging and inhibi-
tory control of action: cortico-subthalamic connection strength pre-
dicts stopping performance. J Neurosci 2012; 32: 8401–12.
Cubillo A, Smith AB, Barrett N, Giampietro V, Brammer MJ,
Simmons A, et al. Shared and drug-speciﬁc effects of atomoxetine
and methylphenidate on inhibitory brain dysfunction in medication-
naive ADHD boys. Cereb Cortex 2014; 24: 174–85.
Cummins TD, Hawi Z, Hocking J, Strudwick M, Hester R, Garavan
H, et al. Dopamine transporter genotype predicts behavioural and
neural measures of response inhibition. Mol Psychiatry 2012; 17:
1086–92.
David O, Guillemain I, Saillet S, Reyt S, Deransart C, Segebarth C,
et al. Identifying neural drivers with functional MRI: an electro-
physiological validation. PLoS Biol 2008; 6: 2683–97.
Duann JR, Ide JS, Luo X, Li CS. Functional connectivity delin-
eates distinct roles of the inferior frontal cortex and presupplemen-
tary motor area in stop signal inhibition. J Neurosci 2009; 29:
10171–9.
Eagle DM, Bari A, Robbins TW. The neuropsychopharmacology of
action inhibition: cross-species translation of the stop-signal and go/
no-go tasks. Psychopharmacology 2008; 199: 439–56.
Eagle DM, Baunez C. Is there an inhibitory-response-control system in
the rat? Evidence from anatomical and pharmacological studies of
behavioral inhibition. Neurosci Biobehav Rev 2010; 34: 50–72.
Forstmann BU, Keuken MC, Jahfari S, Bazin PL, Neumann J, Schafer
A, et al. Cortico-subthalamic white matter tract strength predicts
interindividual efﬁcacy in stopping a motor response. Neuroimage
2012; 60: 370–5.
Frank MJ, Samanta J, Moustafa AA, Sherman SJ. Hold your horses:
impulsivity, deep brain stimulation, and medication in parkinsonism.
Science 2007; 318: 1309–12.
Friston K, Moran R, Seth AK. Analysing connectivity with Granger
causality and dynamic causal modelling. Curr Opin Neurobiol
2013; 23: 172–8.
Friston KJ, Harrison L, Penny W. Dynamic causal modelling.
Neuroimage 2003; 19: 1273–302.
Gilbert JR, Symmonds M, Hanna MG, Dolan RJ, Friston KJ, Moran
RJ. Proﬁling neuronal ion channelopathies with non-invasive brain
imaging and dynamic causal models: case studies of single gene
mutations. Neuroimage 2016; 124(Pt A): 43–53.
Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of
Lewy pathology. Nat Rev 2013; 9: 13–24.
Goldstein DS, Sullivan P, Holmes C, Kopin IJ, Basile MJ, Mash DC.
Catechols in post-mortem brain of patients with Parkinson disease.
Eur J Neurol 2011; 18: 703–10.
Goulden N, McKie S, Thomas EJ, Downey D, Juhasz G, Williams SR,
et al. Reversed frontotemporal connectivity during emotional
face processing in remitted depression. Biol Psychiatry 2012; 72:
604–11.
Herz DM, Haagensen BN, Christensen MS, Madsen KH, Rowe JB,
Lokkegaard A, et al. The acute brain response to levodopa heralds
dyskinesias in Parkinson disease. Ann Neurol 2014; 75: 829–36.
Herz DM, Haagensen BN, Christensen MS, Madsen KH, Rowe JB,
Lokkegaard A, et al. Abnormal dopaminergic modulation of striato-
cortical networks underlies levodopa-induced dyskinesias in humans.
Brain 2015; 138(Pt 6): 1658–66.
Hughes LE, Barker RA, Owen AM, Rowe JB. Parkinson’s disease and
healthy aging: independent and interacting effects on action selec-
tion. Hum Brain Mapp 2010; 31: 1886–99.
Hughes LE, Altena E, Barker RA, Rowe JB. Perseveration and choice
in Parkinson’s disease: the impact of progressive frontostriatal dys-
function on action decisions. Cereb Cortex 2013; 23: 1572–81.
Huot P, Fox SH, Brotchie JM. Monoamine reuptake inhibitors in
Parkinson’s disease. Parkinson’s Dis 2015; 2015: 609428.
Iannetti GD, Wise RG. BOLD functional MRI in disease and pharma-
cological studies: room for improvement? Magn Reson Imaging
2007; 25: 978–88.
Kahan J, Urner M, Moran R, Flandin G, Marreiros A, Mancini L,
et al. Resting state functional MRI in Parkinson’s disease: the impact
of deep brain stimulation on ‘effective’ connectivity. Brain 2014;
137(Pt 4): 1130–44.
Kass RE, Raftery AE. Bayes factors. J Ame Stati Assoc 1995; 90: 773–
95.
Kehagia AA, Housden CR, Regenthal R, Barker RA, Muller U, Rowe
J, et al. Targeting impulsivity in Parkinson’s disease using atomox-
etine. Brain 2014; 137(Pt 7): 1986–97.
Logan GD, Cowan WB. On the ability to inhibit thought and action: a
theory of an act of control. Psychol Rev 1984; 91: 295–327.
Logan J, Wang GJ, Telang F, Fowler JS, Alexoff D, Zabroski J, et al.
Imaging the norepinephrine transporter in humans with (S,S)-
[11C]O-methyl reboxetine and PET: problems and progress. Nucl
Med Biol 2007; 34: 667–79.
Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for
the treatment of executive dysfunction in Parkinson’s disease: a pilot
open-label study. Mov Disord 2009; 24: 277–82.
Michely J, Volz LJ, Barbe MT, Hoffstaedter F, Viswanathan S,
Timmermann L, et al. Dopaminergic modulation of motor network
dynamics in Parkinson’s disease. Brain 2015; 138: 664–78.
Response inhibition network in PD BRAIN 2016: 139; 2235–2248 | 2247
 by guest on A
ugust 10, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
Mirabella G, Iaconelli S, Romanelli P, Modugno N, Lena F, Manfredi
M, et al. Deep brain stimulation of subthalamic nuclei affects arm
response inhibition in Parkinson’s patients. Cereb Cortex 2012; 22:
1124–32.
Moppett IK, Sherman RW, Wild MJ, Latter JA, Mahajan RP. Effects
of norepinephrine and glyceryl trinitrate on cerebral haemo-
dynamics: transcranial Doppler study in healthy volunteers. Br J
Anaesth 2008; 100: 240–4.
Moran RJ, Campo P, Symmonds M, Stephan KE, Dolan RJ, Friston
KJ. Free energy, precision and learning: the role of cholinergic neu-
romodulation. J Neurosci 2013; 33: 8227–36.
Nambu A, Tokuno H, Takada M. Functional signiﬁcance of the cor-
tico-subthalamo-pallidal ‘hyperdirect’ pathway. Neurosci Res 2002;
43: 111–7.
Nandam LS, Hester R, Wagner J, Dean AJ, Messer C, Honeysett A,
et al. Dopamine D(2) receptor modulation of human response in-
hibition and error awareness. J Cogn Neurosci 2013; 25: 649–56.
Napier TC, Corvol JC, Grace AA, Roitman JD, Rowe J, Voon V, et al.
Linking neuroscience with modern concepts of impulse control dis-
orders in Parkinson’s disease. Mov Disord 2014; 30: 141–9.
Nombela C, Rittman T, Robbins TW, Rowe JB. Multiple modes of
impulsivity in Parkinson’s disease. PloS One 2014a; 9: e85747.
Nombela C, Rowe JB, Winder-Rhodes SE, Hampshire A, Owen AM,
Breen DP, et al. Genetic impact on cognition and brain function in
newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain
2014b; 137(Pt 10): 2743–58.
Obeso I, Wilkinson L, Casabona E, Bringas ML, Alvarez M, Alvarez
L, et al. Deﬁcits in inhibitory control and conﬂict resolution on
cognitive and motor tasks in Parkinson’s disease. Exp Brain Res
2011a; 212: 371–84.
Obeso I, Wilkinson L, Jahanshahi M. Levodopa medication does not
inﬂuence motor inhibition or conﬂict resolution in a conditional
stop-signal task in Parkinson’s disease. Exp Brain Res 2011b; 213:
435–45.
Penny WD, Stephan KE, Daunizeau J, Rosa MJ, Friston KJ, Schoﬁeld
TM, et al. Comparing families of dynamic causal models. PLoS
Comput Biol 2010; 6: e1000709.
Rae CL, Correia MM, Altena E, Hughes LE, Barker RA, Rowe JB.
White matter pathology in Parkinson’s disease: The effect of imaging
protocol differences and relevance to executive function.
Neuroimage 2012; 62: 1675–84.
Rae CL, Hughes LE, Weaver C, Anderson MC, Rowe JB. Selection
and stopping in voluntary action: a meta-analysis and combined
fMRI study. Neuroimage 2014; 86: 381–91.
Rae CL, Hughes LE, Anderson MC, Rowe JB. The prefrontal cortex
achieves inhibitory control by facilitating subcortical motor pathway
connectivity. J Neurosci 2015; 35: 786–94.
Ray NJ, Brittain JS, Holland P, Joundi RA, Stein JF, Aziz TZ, et al.
The role of the subthalamic nucleus in response inhibition: evidence
from local ﬁeld potential recordings in the human subthalamic nu-
cleus. Neuroimage 2012; 60: 271–8.
Redgrave P, Rodriguez M, Smith Y, Rodriguez-Oroz MC, Lehericy S,
Bergman H, et al. Goal-directed and habitual control in the basal
ganglia: implications for Parkinson’s disease. Nat Rev Neurosci
2010; 11: 760–72.
Rigoux L, Stephan KE, Friston KJ, Daunizeau J. Bayesian model se-
lection for group studies - revisited. Neuroimage 2014; 84: 971–85.
Rowe JB. Connectivity analysis is essential to understand neurological
disorders. Fron Syst Neurosci 2010; 4: 144.
Rowe JB, Hughes LE, Barker RA, Owen AM. Dynamic causal model-
ling of effective connectivity from fMRI: are results reproducible and
sensitive to Parkinson’s disease and its treatment? Neuroimage
2010; 52: 1015–26.
Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomox-
etine. Clin Pharmacokinet 2005; 44: 571–90.
Shafto MA, Tyler LK, Dixon M, Taylor JR, Rowe JB, Cusack R, et al.
The Cambridge Centre for Ageing and Neuroscience (Cam-CAN)
study protocol: a cross-sectional, lifespan, multidisciplinary examin-
ation of healthy cognitive ageing. BMC Neurol 2014; 14: 204.
Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE,
Mackay CE, et al. Tract-based spatial statistics: voxelwise analysis
of multi-subject diffusion data. Neuroimage 2006; 31: 1487–505.
Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing
problems of smoothing, threshold dependence and localisation in
cluster inference. Neuroimage 2009; 44: 83–98.
Song C, Schwarzkopf DS, Lutti A, Li B, Kanai R, Rees G.
Effective connectivity within human primary visual cortex predicts
interindividual diversity in illusory perception. J Neurosci 2013; 33:
18781–91.
Stephan KE, Kasper L, Harrison LM, Daunizeau J, den Ouden HE,
Breakspear M, et al. Nonlinear dynamic causal models for fMRI.
Neuroimage 2008; 42: 649–62.
Stephan KE, Penny WD, Daunizeau J, Moran RJ, Friston KJ. Bayesian
model selection for group studies. Neuroimage 2009a; 46: 1004–17.
Stephan KE, Tittgemeyer M, Knosche TR, Moran RJ, Friston KJ.
Tractography-based priors for dynamic causal models.
Neuroimage 2009b; 47: 1628–38.
Stephan KE, Penny WD, Moran RJ, den Ouden HE, Daunizeau J,
Friston KJ. Ten simple rules for dynamic causal modeling.
Neuroimage 2010; 49: 3099–109.
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE.
Systematic review of levodopa dose equivalency reporting in
Parkinson’s disease. Mov Disord 2010; 25: 2649–53.
van der Schaaf ME, Zwiers MP, van Schouwenburg MR, Geurts DE,
Schellekens AF, Buitelaar JK, et al. Dopaminergic drug effects during
reversal learning depend on anatomical connections between the orbi-
tofrontal cortex and the amygdala. Front Neurosci 2013; 7: 142.
van Schouwenburg MR, Zwiers MP, van der Schaaf ME, Geurts DE,
Schellekens AF, Buitelaar JK, et al. Anatomical connection strength
predicts dopaminergic drug effects on fronto-striatal function.
Psychopharmacology 2013; 227: 521–31.
Vazey EM, Aston-Jones G. The emerging role of norepinephrine in
cognitive dysfunctions of Parkinson’s disease. Front Behav
Neurosci 2012; 6: 48.
Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N,
et al. Chronic dopaminergic stimulation in Parkinson’s disease: from
dyskinesias to impulse control disorders. Lancet Neurol 2009; 8:
1140–9.
Wang LE, Fink GR, Diekhoff S, Rehme AK, Eickhoff SB, Grefkes C.
Noradrenergic enhancement improves motor network connectivity
in stroke patients. Ann Neurol 2011; 69: 375–88.
Wheeler-Kingshott C, Cercignani M. About “axial” and “radial” dif-
fusivities. Magn Res Med 2009; 61: 1255–60.
Whelan R, Conrod PJ, Poline JB, Lourdusamy A, Banaschewski T,
Barker GJ, et al. Adolescent impulsivity phenotypes characterized
by distinct brain networks. Nat Neurosci 2012; 15: 920–5.
Wiecki TV, Frank MJ. A computational model of inhibitory control in
frontal cortex and basal ganglia. Psychol Rev 2013; 120: 329–55.
Yamamoto BK, Novotney S. Regulation of extracellular dopamine by
the norepinephrine transporter. J Neurochem 1998; 71: 274–80.
Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ,
et al. Characterizing mild cognitive impairment in incident Parkinson
disease: the ICICLE-PD study. Neurology 2014; 82: 308–16.
Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T,
et al. Selective serotonin reuptake inhibition modulates response in-
hibition in Parkinson’s disease. Brain 2014; 137(Pt 4): 1145–55.
Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T,
et al. Improving response inhibition in Parkinson’s disease with ato-
moxetine. Biol Psychiatry 2015; 77: 740–8.
Ye Z, Rae CL, Nombela C, Ham T, Rittman T, Jones PS, et al.
Predicting beneﬁcial effects of atomoxetine and citalopram on re-
sponse inhibition in Parkinson’s disease with clinical and neuroima-
ging measures. Hum Brain Mapp 2016; 37: 1026–37.
2248 | BRAIN 2016: 139; 2235–2248 C. L. Rae et al.
 by guest on A
ugust 10, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
